Welcome to our dedicated page for Aethlon Medical news (Ticker: AEMD), a resource for investors and traders seeking the latest updates and insights on Aethlon Medical stock.
Aethlon Medical, Inc. develops the investigational Aethlon Hemopurifier, an extracorporeal therapeutic device for oncology and other indications. Company news centers on clinical-stage development in solid tumors and infectious-disease applications, including safety, feasibility and dose-finding work for Hemopurifier treatments used alongside anti-PD-1 therapies such as pembrolizumab or nivolumab.
Recurring updates also address preclinical research on the device's GNA affinity resin, extracellular vesicle removal and inflammatory microRNAs, along with quarterly financial results, corporate updates and investor presentations. The company's disclosures describe a platform designed to selectively remove circulating pathogenic targets from biologic fluids.
Aethlon Medical (Nasdaq:AEMD) announced peer-reviewed research identifying a novel Long COVID biomarker and target for its Hemopurifier® device. The study found significantly increased mannosylated extracellular vesicles (EVs) in Long COVID patients, which were captured using the same Galanthus nivalis agglutinin (GNA) affinity resin used in the Hemopurifier.
Key findings include roughly two-fold higher mannose-positive EVs in Long COVID, successful capture of disease-associated small EVs, significant reduction of seven immune-related microRNAs after GNA resin treatment, and pathway analysis implicating JAK-STAT, VEGF, PI3K, and estrogen signaling. The results support EVs as a potential therapeutic target and provide a translational framework for future Hemopurifier studies in Long COVID.
The editorial reviews how biotech and medical tech companies are responding to the 2026 Ebola/Bundibugyo virus outbreak, which has caused over 1,000 cases and 260 deaths. It highlights vaccine and therapeutic efforts by Soligenix (SNGX), Aethlon Medical (NASDAQ:AEMD), Regeneron (REGN), and Moderna (MRNA).
Soligenix and collaborators report thermostable multivalent filovirus vaccines with up to 100% protection in non-human primates. Aethlon’s Hemopurifier investigational device was used during the 2014 Ebola outbreak under emergency use. Regeneron’s maftivimab has been prioritized by WHO for Bundibugyo trials, while Moderna received up to $50 million from CEPI to advance an mRNA Bundibugyo vaccine.
Aethlon Medical (Nasdaq:AEMD) reported fiscal year ended March 31, 2026 results and a corporate update. The company advanced its Australian oncology trial into Cohort 3, with the first participant completing three Hemopurifier treatments without device deficiencies or immediate complications.
Aethlon expanded Hemopurifier intellectual property, including U.S. and European patents for Long COVID and acute COVID-19 coagulopathy extending into the 2040s, and advanced preclinical work in rheumatoid arthritis and chronic kidney disease. Operating expenses fell 21.9% to about $7.3 million, and net loss narrowed to $7.2 million. Cash was roughly $5.0 million, plus $1.85 million raised post year-end via an at-the-market program.
Aethlon Medical (Nasdaq:AEMD) will release fiscal year-end results for the period ended March 31, 2026 at 4:15 p.m. ET on Wednesday, June 10, 2026. Management will host a conference call at 4:30 p.m. ET, followed by a Q&A session, with replay available through July 10, 2026.
Aethlon Medical (NASDAQ:AEMD) is monitoring the current Bundibugyo Ebola virus outbreak in the Democratic Republic of the Congo and Uganda and remains prepared to discuss potential investigational use of its Hemopurifier with global health and regulatory authorities.
The Hemopurifier is an investigational device designed to remove enveloped viruses. In a 2014 emergency-use case in Germany, a critically ill Ebola (Zaire strain) patient received a single 6.5-hour treatment, with reported viral load decline from ~400,000 to ~1,000 copies/mL and undetectable virus five days later. The FDA previously granted an IDE supplement enabling a regulatory pathway for investigational Hemopurifier use in Ebola patients in the U.S. The device remains investigational, and Aethlon will continue to monitor the outbreak and respond to clinician inquiries.
Aethlon Medical (NASDAQ: AEMD) announced the independent DSMB completed a safety review of cohort 2 in its AEMD-2022-06 trial on March 24, 2026 and recommended advancing to cohort 3. No device-related SAEs or DLTs were reported and cohort 3 enrollment is open to receive three Hemopurifier treatments over one week.
The study (9–18 patients) evaluates safety, feasibility and dose-finding in patients with solid tumors receiving pembrolizumab or nivolumab, with primary endpoints focused on adverse events and safety labs.
Aethlon Medical (Nasdaq: AEMD) reported that an independent DSMB completed a safety review of cohort 2 in its AEMD-2022-06 oncology trial and recommended advancing to the third and final cohort. The DSMB found no safety concerns, with no device-related SAEs or DLTs reported to date.
Enrollment for Cohort 3 is open; participants will receive three Hemopurifier treatments over one week at three active clinical sites in Australia. Results will inform a future PMA study.
Aethlon Medical (Nasdaq: AEMD) has engaged Maxim Group LLC as exclusive financial advisor to evaluate strategic opportunities including partnerships, mergers, acquisitions or other transactions.
The company completed the second cohort of its Australian oncology trial and will submit safety data to the independent Data Safety Monitoring Board. No timeline or assurance of a transaction has been established.
Aethlon Medical (Nasdaq: AEMD) will present at the Emerging Growth Conference on February 25, 2026 from 12:30–1:00 PM ET. The live, interactive online presentation features a fireside chat with CEO and CFO Jim Frakes and a real-time Q&A for investors.
Registration is required to attend; an archived webcast will be posted on EmergingGrowth.com and the Emerging Growth YouTube channel after the event.
Aethlon Medical (Nasdaq: AEMD) reported fiscal Q3 results for the period ended December 31, 2025, while advancing clinical and R&D programs. Key facts: cash balance ~$7.0 million, Q3 operating loss of $2.06 million, and nine-month operating expenses down 26.9%. Cohort 2 enrollment in the Australian oncology trial is underway, EV Long COVID preclinical data published on bioRxiv, and an MTA with Stavro is evaluating Hemopurifier compatibility with a simplified blood treatment system.